Navigation Links
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone)
Date:9/17/2010

SILVER SPRING, Md., Sept. 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The preliminary results are based on five-year data from an ongoing, 10-year observational study by the manufacturer, Takeda Pharmaceuticals North America Inc., San Diego. These early results showed no overall association between Actos exposure and risk of bladder cancer. However, there was an increased risk of bladder cancer in patients with the longest exposure to Actos and in those with the highest cumulative dose of the drug.

At this time, the FDA's review is ongoing. The agency has not concluded that Actos increases the risk of bladder cancer.

Actos (pioglitazone) is used to control blood sugar in patients with type 2 diabetes mellitus. It is in the class of drugs known as peroxisome proliferator-activated receptor (PPAR) agonists. The only other drug in this class is Avandia (rosiglitazone).  The FDA has no clinical information associating Avandia with bladder cancer in patients receiving that drug.  

Patients should talk to their health care professional if they have concerns about Actos. They should not stop taking the drug unless told to do so by their health care professional.

For more information

Ongoing Safety Review of Actos (pioglitazone) and Increased Risk of Bladder Cancer

http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm


'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Reviewing Biomoda Submission for Cancer Screening Study
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
9. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
(Date:8/28/2015)... 2015 The scientific team of a ... of the leading academics in the field of aging Prof. ... in life extension for model animals - 10 fold for ... and age-related diseases, primarily, around the stability and stress resistance ... published as "Stability analysis of a model gene network links ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... ZeaVision, LLC announced two internal promotions as the ... its leading EyePromise® nutraceutical products featuring ... to President effective immediately from his previous role of ... appointment to the ZeaVision Executive Board. Founder, ...
... Sept. 1 In recognition of September,s designation as ... Pain Physicians (ASIPP) today announced that it is planning ... life for the approximately 75 million Americans suffering from ... this outreach, ASIPP has developed a consumer section on ...
Cached Medicine Technology:Nutraceutical Leader Announces Internal Promotions of Key Personnel 2American Society of Interventional Pain Physicians (ASIPP) Promotes Patient Education and Outreach Initiatives During National Pain Awareness Month 2
(Date:8/30/2015)... ... 30, 2015 , ... Scientists in France say asbestos exposure may put workers ... Surviving Mesothelioma has just posted an article on the new research. Click here ... cancer incidence among 2,024 French asbestos plant workers from 1978 to 2009. In addition ...
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 ... ... that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant to ... you’ll interact with a proven professional, focused on your goals. Kathleen graduated ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, ... that it will be devoting an entire short segment to the subject of diabetes. ... the globe on a daily basis, but recent advancements in medical science may prove ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... at the University of Illinois at Chicago, in collaboration with ... precisely how the antibiotic linezolid inhibits bacterial growth. ... first new antibiotic to enter the marketplace in 30 years ... of the cell. But exactly where the binding occurred and ...
... Andhra Pradesh Chief Minister Y.S. Rajasekhara Reddy, who is ... University to set up an offshore campus in Hyderabad, ... ,The chief minister made the request after the signing ... and Satyam Computers' EMRI (Emergency Management and Research Institute) ...
... say they have developed a technique to attack and ... as nausea or hair loss. ,They ... attack cancer cells, but leave healthy tissue unaffected. ... with anti-cancer antibodies so they zero in on their ...
... struck Salisbury, suburb north of the Adelaide capital of the ... kid , sliding down in a popular playground, came into ... is not clear what happened to the kid, but a ... gone wrong. ,Health authorities described the chemical as ...
... People with HIV who drop out of care do not ... treatment, said Baylor College of Medicine and Veterans Affairs ... of Clinical Infectious Diseases and available on line. ... (the human immunodeficiency virus that causes AIDS) is keeping people ...
... artificial plastic blood, which they claim could act as a ... in war zones. ,The new artificial blood ... atom at their core, like haemoglobin, that can carry oxygen ... looking for extra funding to develop a final prototype that ...
Cached Medicine News:Health News:Researchers Discover How Antibiotic Inhibits Bacterial Growth 2Health News:Reddy Asks Stanford University to Open Hyderabad Campus 2Health News:New Cancer Therapy That can Be Less Painful 2Health News:Children Using Slide in Playground Treated for Exposure to Poisoning 2Health News:HIV Survival Improves If Patients Stay in Care 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: